page_title: TopoTarget
section_title: HSP90 inhibitors
hierarchical_section_title: TopoTarget / Products / Pre-clinical development / HSP90 inhibitors
caption_attribution_description: English: author: Tirkfl, based on the PDB entry 2CG9
context_page_description: TopoTarget was a Copenhagen-based biotechnology company focused on the discovery and development of drugs and therapies to treat cancer. In 2014, it merged with BioAlliance Pharma and is now part of Onxeo.
  It was founded in 2000 by a group of clinicians. TopoTarget was involved in collaborations with both academia and industry. In 2001 they began collaborating with the National Cancer Institute, a component of the US National Institutes of Health. Since their acquisition of Prolifix, they have been collaborating with the Netherlands Cancer Institute. They also collaborate with Rigshospitalet, the national hospital of Denmark. TopoTarget has also collaborated with other companies, including Novartis since 2003, and Lundbeck as of October 2007; Topotarget has been member of the Danish Innovation Network Biopeople since 2005.
context_section_description: A number of heat shock protein 90 (HSP90) small molecule inhibitors have been developed by TopoTarget, with several compounds showing high potency in several cancer cell lines, particularly those cell lines which over-express HER2 receptors.  This project is still in pre-clinical trials and TopoTarget is in the process of out-licensing the product or looking for companies to collaborate with on the project.
caption: Heat shock proteins are vital to eukaryotic cell function and are among the most highly expressed proteins in all species. HSP90 facilitates protein folding, cell signaling, and tumor repression. Inhibition of HSP90 interferes with the PI3K/AKT pathway, initiating apoptosis, making HSP90 inhibitors attractive prospects for cancer treatment.
exif: {}